Big Pharma Finds Lucrative Market Among Africa's Middle Classes.

Reuters (2/13, Berton) reports that a surge in economic growth in Africa is attracting pharmaceutical giants, such as GlaxoSmithKline and Novartis, to expand their presence on the continent. The drug makers say one of the biggest incentives is the market to treat chronic diseases among the Middle Classes. Moreover, according to the most recent data from the IMS, by 2016, Africa's 10.6 percent annual growth rate will help boost its pharmaceutical spending to as much as $30 billion; and analysts are projecting that by 2020, the market will reach $45 billion. However, the potential benefits are not without challenges. Yet, even the recent violence in Mali and Algeria wasn't enough to deter Paris-based Sanofi SA from moving forward with what will be its third drug-manufacturing facility in Africa.

from DIA Daily

DIA Daily. This daily enewsletter features summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. This easy-to-read enewsletter is delivered to your inbox every business morning.

Subscribe to the DIA Daily.
View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191

 

 

J&J Permits Generic Production Of Patented HIV Drug to benefit sub-saharan Africa and poor countries

J&J Permits Generic Production Of Patented HIV Drug.

Bloomberg News (11/30, Armstrong) reports Johnson & Johnson announced it would allow generic-drug manufacturers to "make and distribute copies of its HIV medicine Prezista [darunavir] in sub-Saharan Africa and poor countries." The New Brunswick, New Jersey, pharmaceutical company said it "won't enforce patent claims" against drugmakers that produce generic copies of its antiretroviral drug. However, the J&J agreement "says that generics manufacturers can only distribute the medicine for patients living in the African and least-developed countries." According to the WHO, about "34.2 million people worldwide are infected with HIV, including 22.9 million in Africa."

        Reuters (11/30, Hirschler) notes that J&J already has one such agreement under which Durban, South Africa-based Aspen Pharmacare produces darunavir at a $2.22 daily price. AFP (11/30) also covers the J&J announcement.

DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org. Click here to check your membership status.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044

Copyright © 2012 by BulletinHealthcare | 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191